#METABOLOMICS WORKBENCH line@sund.ku.dk_20161102_999999 DATATRACK_ID:774 STUDY_ID:ST000502 ANALYSIS_ID:AN000771 PROJECT_ID:PR000379 VERSION 1 CREATED_ON November 10, 2016, 8:20 am #PROJECT PR:PROJECT_TITLE Weight loss and weight maintenance obtained with or without GLP-1 analogue PR:PROJECT_TITLE treatment decrease branched chain amino acid levels PR:PROJECT_TYPE NMR PR:PROJECT_SUMMARY RCT on the effect of liraglutide on weight maintenance during 1 year PR:INSTITUTE University of Copenhagen, Denmark PR:DEPARTMENT Section of Novo Nordisk Foundation Center for Basic Metabolic Research, Section PR:DEPARTMENT of Metabolic Genetics, Faculty of Health Sciences, University of Copenhagen, PR:DEPARTMENT Denmark. 2 Novo Nordisk Foundation Center for Basic Metabolic Research, Section PR:DEPARTMENT of Metabolic Genetics and Department of Biomedical Sciences, Faculty of Health PR:DEPARTMENT Sciences PR:LAST_NAME Engelbrechtsen PR:FIRST_NAME Line PR:ADDRESS Section of Metabolic Genetics, Universitetsparken 1, DIKU building 1st floor, PR:ADDRESS 2100 Copenhagen PR:EMAIL line@sund.ku.dk PR:PHONE +4535333639 PR:FUNDING_SOURCE The study incl. purchase of Victoza pens was supported by funding from The PR:FUNDING_SOURCE Danish Research Council for Health and Disease (ref. no: 11-107683), the PR:FUNDING_SOURCE University Investment Capital (UNIK): Food, Fitness & Pharma for Health and PR:FUNDING_SOURCE Disease from the Danish Ministry of Science, Technology and Innovation and the PR:FUNDING_SOURCE Danish Diabetes Academy funded by the Novo Nordisk Foundation. Cambridge Weight PR:FUNDING_SOURCE Plan products were donated from Cambridge Weight Plan. #STUDY ST:STUDY_TITLE Weight loss and weight maintenance obtained with or without GLP-1 analogue ST:STUDY_TITLE treatment decrease branched chain amino acid levels. ST:STUDY_TYPE RCT ST:STUDY_SUMMARY RCT of the effect og liraglutide on weight maintenance. 58 individuals wer ST:STUDY_SUMMARY included and subjected to low calorie intake during 8 weeks. Individuals lost a ST:STUDY_SUMMARY mean of 12 kg during that period. Individuals were then randomized to receive ST:STUDY_SUMMARY 1.2 mg liraglutide daily for 1 year or serving as control. Metabolites were ST:STUDY_SUMMARY measured at inclusion (-8 weeks), randomization (0 weeks) and at 4 and 52 weeks ST:STUDY_SUMMARY during weight maintenance. ST:INSTITUTE NNF Center for Metabolic Research ST:LAST_NAME Engelbrechtsen ST:FIRST_NAME Line ST:ADDRESS Section of Metabolic Genetics, Universitetsparken 1, DIKU building 1st floor, ST:ADDRESS 2100 Copenhagen ST:EMAIL line@sund.ku.dk ST:PHONE +4535333639 ST:NUM_GROUPS 2 ST:TOTAL_SUBJECTS 58 #SUBJECT SU:SUBJECT_TYPE Humans SU:SUBJECT_SPECIES Homo sapiens SU:TAXONOMY_ID 9606 #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data SUBJECT_SAMPLE_FACTORS - -8_1 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - -8_2 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_3 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - -8_5 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_6 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - -8_7 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - -8_8 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - -8_9 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_10 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_11 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - -8_12 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - -8_14 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_15 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - -8_17 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_19 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_20 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - -8_21 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - -8_22 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - -8_23 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_24 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - -8_25 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_26 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - -8_27 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_28 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - -8_29 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - -8_30 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_31 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_33 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_34 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - -8_35 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - -8_36 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_37 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_38 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_39 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_40 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - -8_41 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - -8_42 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - -8_43 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_44 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_45 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_46 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - -8_47 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_48 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_49 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - -8_50 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_51 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - -8_52 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_53 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_54 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - -8_57 Time(weeks):-8 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - -8_58 Time(weeks):-8 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_1 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_2 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_3 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_5 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_6 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_7 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_8 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_9 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_10 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_11 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_12 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_14 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_15 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_16 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_17 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_19 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_20 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_21 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_22 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_23 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_24 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_25 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_26 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_27 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_28 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_29 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_30 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_31 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_33 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_34 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_35 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_36 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_37 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_38 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_39 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_40 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_41 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_42 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_43 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_44 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_45 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_46 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_47 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_48 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_49 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_50 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_51 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_52 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_53 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_54 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 0_57 Time(weeks):- | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 0_58 Time(weeks):- | Treatment:Control SUBJECT_SAMPLE_FACTORS - 4_1 Time(weeks):4 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 4_2 Time(weeks):4 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 4_5 Time(weeks):4 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 4_7 Time(weeks):4 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 4_8 Time(weeks):4 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 4_10 Time(weeks):4 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 4_11 Time(weeks):4 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 4_12 Time(weeks):4 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 4_14 Time(weeks):4 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 4_15 Time(weeks):4 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 4_17 Time(weeks):4 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 4_20 Time(weeks):4 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 4_21 Time(weeks):4 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 4_22 Time(weeks):4 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 4_23 Time(weeks):4 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 4_24 Time(weeks):4 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 4_25 Time(weeks):4 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 4_26 Time(weeks):4 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 4_27 Time(weeks):4 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 4_28 Time(weeks):4 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 4_29 Time(weeks):4 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 4_30 Time(weeks):4 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 4_31 Time(weeks):4 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 4_33 Time(weeks):4 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 4_34 Time(weeks):4 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 4_35 Time(weeks):4 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 4_36 Time(weeks):4 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 4_37 Time(weeks):4 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 4_38 Time(weeks):4 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 4_39 Time(weeks):4 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 4_40 Time(weeks):4 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 4_42 Time(weeks):4 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 4_43 Time(weeks):4 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 4_44 Time(weeks):4 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 4_45 Time(weeks):4 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 4_46 Time(weeks):4 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 4_47 Time(weeks):4 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 4_48 Time(weeks):4 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 4_49 Time(weeks):4 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 4_50 Time(weeks):4 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 4_51 Time(weeks):4 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 4_52 Time(weeks):4 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 4_53 Time(weeks):4 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 4_54 Time(weeks):4 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 4_57 Time(weeks):4 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 4_58 Time(weeks):4 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 52_1 Time(weeks):52 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 52_2 Time(weeks):52 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 52_3 Time(weeks):52 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 52_5 Time(weeks):52 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 52_6 Time(weeks):52 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 52_7 Time(weeks):52 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 52_8 Time(weeks):52 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 52_9 Time(weeks):52 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 52_10 Time(weeks):52 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 52_11 Time(weeks):52 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 52_12 Time(weeks):52 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 52_14 Time(weeks):52 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 52_15 Time(weeks):52 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 52_16 Time(weeks):52 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 52_16 Time(weeks):52 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 52_17 Time(weeks):52 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 52_19 Time(weeks):52 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 52_20 Time(weeks):52 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 52_21 Time(weeks):52 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 52_22 Time(weeks):52 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 52_23 Time(weeks):52 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 52_25 Time(weeks):52 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 52_26 Time(weeks):52 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 52_27 Time(weeks):52 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 52_28 Time(weeks):52 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 52_29 Time(weeks):52 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 52_30 Time(weeks):52 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 52_34 Time(weeks):52 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 52_36 Time(weeks):52 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 52_37 Time(weeks):52 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 52_38 Time(weeks):52 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 52_39 Time(weeks):52 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 52_40 Time(weeks):52 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 52_41 Time(weeks):52 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 52_42 Time(weeks):52 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 52_43 Time(weeks):52 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 52_44 Time(weeks):52 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 52_45 Time(weeks):52 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 52_46 Time(weeks):52 | Treatment:Control SUBJECT_SAMPLE_FACTORS - 52_47 Time(weeks):52 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 52_48 Time(weeks):52 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 52_52 Time(weeks):52 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 52_57 Time(weeks):52 | Treatment:GLP-1 analogue SUBJECT_SAMPLE_FACTORS - 52_58 Time(weeks):52 | Treatment:Control #COLLECTION CO:COLLECTION_SUMMARY The samples analyzed were obtained in a fasting state. Samples were taken at CO:COLLECTION_SUMMARY inclusion, after 8 weeks of weight loss (baseline), and after 4 and 52 weeks of CO:COLLECTION_SUMMARY weight maintenance. CO:COLLECTION_PROTOCOL_ID ClinicalTrials.gov Identifier: NCT02094183 #TREATMENT TR:TREATMENT_SUMMARY 22 indivuals received 1.2 mg of liraglutide injections (Victoza, Novo TR:TREATMENT_SUMMARY Nordisk)daily for 1 year, 20 controls did not receive treatment #SAMPLEPREP SP:SAMPLEPREP_SUMMARY Prior to the NMR measurements, 260 μL of EDTA plasma and 260 μL of a sodium SP:SAMPLEPREP_SUMMARY phosphate buffer (75 mmol/L Na2HPO4 in 80%/20% H2O/D2O, pH 7.4; including also SP:SAMPLEPREP_SUMMARY 0.08% sodium 3-(trimethylsilyl)propionate-2,2,3,3-d4 and 0.04% sodium azide) was SP:SAMPLEPREP_SUMMARY mixed and moved to the NMR tubes. All the liquid handling steps for plasma SP:SAMPLEPREP_SUMMARY samples were done with a PerkinElmer JANUS Automated Workstation. The NMR SP:SAMPLEPREP_SUMMARY metabolomics laboratory setup combined Bruker AVANCE III 500 MHz and Bruker SP:SAMPLEPREP_SUMMARY AVANCE III HD 600 MHz spectrometers #CHROMATOGRAPHY CH:CHROMATOGRAPHY_TYPE - CH:INSTRUMENT_NAME - CH:COLUMN_NAME - #ANALYSIS AN:ANALYSIS_TYPE NMR #NMR NM:INSTRUMENT_NAME Bruker Avance III 500 MHz and Bruker AVANCE III HD 600 MHz NM:INSTRUMENT_TYPE FT-NMR NM:NMR_EXPERIMENT_TYPE 1D-1H NM:SPECTROMETER_FREQUENCY 500 and 600 MHz #NMR_METABOLITE_DATA NMR_METABOLITE_DATA:UNITS mmol/l NMR_METABOLITE_DATA_START metabolite_name -8_1 -8_2 -8_3 -8_5 -8_6 -8_7 -8_8 -8_9 -8_10 -8_11 -8_12 -8_14 -8_15 -8_17 -8_19 -8_20 -8_21 -8_22 -8_23 -8_24 -8_25 -8_26 -8_27 -8_28 -8_29 -8_30 -8_31 -8_33 -8_34 -8_35 -8_36 -8_37 -8_38 -8_39 -8_40 -8_41 -8_42 -8_43 -8_44 -8_45 -8_46 -8_47 -8_48 -8_49 -8_50 -8_51 -8_52 -8_53 -8_54 -8_57 -8_58 0_1 0_2 0_3 0_5 0_6 0_7 0_8 0_9 0_10 0_11 0_12 0_14 0_15 0_16 0_17 0_19 0_20 0_21 0_22 0_23 0_24 0_25 0_26 0_27 0_28 0_29 0_30 0_31 0_33 0_34 0_35 0_36 0_37 0_38 0_39 0_40 0_41 0_42 0_43 0_44 0_45 0_46 0_47 0_48 0_49 0_50 0_51 0_52 0_53 0_54 0_57 0_58 4_1 4_2 4_5 4_7 4_8 4_10 4_11 4_12 4_14 4_15 4_17 4_20 4_21 4_22 4_23 4_24 4_25 4_26 4_27 4_28 4_29 4_30 4_31 4_33 4_34 4_35 4_36 4_37 4_38 4_39 4_40 4_42 4_43 4_44 4_45 4_46 4_47 4_48 4_49 4_50 4_51 4_52 4_53 4_54 4_57 4_58 52_1 52_2 52_3 52_5 52_6 52_7 52_8 52_9 52_10 52_11 52_12 52_14 52_15 52_16 52_16 52_17 52_19 52_20 52_21 52_22 52_23 52_25 52_26 52_27 52_28 52_29 52_30 52_34 52_36 52_37 52_38 52_39 52_40 52_41 52_42 52_43 52_44 52_45 52_46 52_47 52_48 52_52 52_57 52_58 Glc 4.09 3.89 4.01 4.81 4.28 4.47 4.55 5.2 4.9 4.23 4.31 4.49 4.82 4.85 4.44 4.04 4.84 4.62 4.45 4.12 4.39 4.32 4.3 4.52 4.57 4.81 4.28 4.85 3.68 4.96 3.74 4.65 4.58 4.74 4.17 3.82 4.63 4.37 4.44 4.65 3.3 3.32 3.9 4.31 4.34 5.11 3.97 3.19 4.34 5.22 4.24 3.61 4.14 3.88 3.93 3.6 4.4 3.8 3.81 3.97 3.97 3.29 4.08 4.27 4.14 3.55 3.29 3.75 4.17 4.17 3.37 3.64 4.11 4.18 4.39 4.43 4.16 4 4.4 4.64 3.39 4.65 4.2 4.49 4.26 4.62 4.33 3.54 4.32 5.08 4.5 4.2 3.4 3.53 4.15 4.19 3.22 4.39 4.74 4.08 4.11 4.9 3.96 3.16 4.21 4.25 3.8 4.04 4.32 3.64 4.28 4.26 4.45 4.28 4.01 4.01 4.19 3.91 4.02 3.78 4.09 3.75 3.93 4.47 4.05 4 3.98 3.69 4.99 3.5 4.03 4.12 4.1 4.37 4.8 4.64 4.8 4.08 3.96 3.69 3.89 4.51 3.53 5.02 4.34 3.92 4.25 3.89 4.09 4.09 3.81 3.99 4.56 3.93 3.96 4.66 4.73 4.61 4.32 4.54 3.89 4.2 4.47 3.63 3.96 4.04 4.16 4.15 4.09 3.07 4.57 4.47 3.58 4.34 4.53 3.31 3.94 3.87 4.52 3.89 3.65 3.71 3.13 3.71 3.81 3.99 4.04 3.3 3.54 3.5 3.44 3.58 3.51 Lac 0.82 0.55 0.64 0.87 1.41 0.46 0.6 0.94 0.86 0.63 0.81 1.34 0.66 1.08 1.09 1.01 0.68 0.62 0.76 0.69 0.75 0.61 0.55 0.97 0.72 0.76 1.22 1.11 0.62 0.77 0.47 0.6 0.74 0.48 0.71 0.63 1.26 0.94 0.54 0.79 0.84 1.58 1.09 1.18 0.67 0.61 0.63 0.51 0.88 0.75 0.54 0.77 0.8 1.27 0.66 0.57 0.66 0.59 0.97 0.81 0.52 0.59 0.8 0.78 1.22 0.48 1.15 0.65 0.51 0.63 1.23 0.53 0.66 0.6 0.61 0.62 0.65 0.61 1.42 0.72 0.6 0.8 0.56 0.92 0.83 0.63 1.87 0.67 0.51 0.85 0.58 0.83 0.63 1.57 0.82 0.8 0.64 0.53 0.93 0.82 0.65 0.52 0.59 0.62 0.55 0.66 0.6 0.94 0.85 0.59 0.43 1.89 0.94 0.51 0.68 0.58 0.54 0.78 0.46 0.57 0.57 1.38 0.84 0.73 0.73 1.66 0.84 0.46 0.98 0.66 0.78 1.01 0.56 1.89 0.49 0.66 0.51 0.58 0.8 1.15 0.96 1.23 1.41 0.62 0.7 0.98 0.62 0.5 0.65 0.64 0.63 1 0.93 0.99 0.57 0.7 0.98 1.01 0.7 0.52 0.8 0.71 2 0.86 0.73 0.68 0.9 0.5 0.62 0.6 1.21 0.59 0.6 0.91 1.14 0.46 0.68 0.72 0.78 0.84 0.62 2.1 0.82 0.39 0.54 0.65 0.54 0.64 0.9 0.97 0.8 0.46 0.9 Pyr 0.1 0.08 0.09 0.12 0.18 0.06 0.07 0.18 0.09 0.08 0.09 0.16 0.1 0.18 0.18 0.16 0.1 0.08 0.12 0.1 0.13 0.09 0.09 0.17 0.12 0.11 0.18 0.18 0.09 0.14 0.07 0.11 0.11 0.09 0.11 0.07 0.21 0.15 0.08 0.14 0.13 0.16 0.15 0.18 0.11 0.11 0.08 0.09 0.15 0.15 0.12 0.14 0.12 0.17 0.09 0.1 0.09 0.08 0.11 0.12 0.09 0.07 0.12 0.11 0.17 0.08 0.17 0.11 0.07 0.11 0.18 0.08 0.1 0.12 0.08 0.11 0.09 0.11 0.18 0.13 0.07 0.08 0.09 0.12 0.15 0.1 0.22 0.14 0.08 0.17 0.09 0.09 0.09 0.21 0.14 0.13 0.09 0.08 0.13 0.14 0.1 0.06 0.12 0.1 0.1 0.11 0.1 0.15 0.11 0.1 0.06 0.27 0.14 0.1 0.13 0.11 0.11 0.14 0.07 0.07 0.07 0.12 0.13 0.13 0.07 0.11 0.11 0.05 0.15 0.09 0.11 0.16 0.06 0.13 0.09 0.11 0.08 0.09 0.08 0.13 0.1 0.11 0.15 0.07 0.11 0.12 0.09 0.05 0.07 0.1 0.12 0.15 0.17 0.17 0.07 0.11 0.19 0.12 0.09 0.06 0.1 0.1 0.27 0.08 0.11 0.11 0.16 0.1 0.13 0.08 0.18 0.13 0.09 0.15 0.13 0.06 0.09 0.12 0.1 0.13 0.08 0.22 0.12 0.12 0.08 0.11 0.08 0.1 0.16 0.15 0.1 0.08 0.14 Cit 0.13 0.12 0.15 0.12 0.15 0.09 0.1 0.11 0.09 0.1 0.12 0.12 0.1 0.09 0.09 0.1 0.09 0.11 0.12 0.09 0.09 0.13 0.05 0.11 0.13 0.1 0.11 0.11 0.08 0.09 0.05 0.1 0.11 0.08 0.1 0.09 0.09 0.11 0.08 0.07 0.09 0.08 0.1 0.07 0.12 0.1 0.08 0.07 0.1 0.09 0.07 0.24 0.22 0.22 0.15 0.2 0.2 0.19 0.12 0.14 0.14 0.12 0.14 0.16 0.18 0.09 0.11 0.18 0.13 0.16 0.12 0.16 0.22 0.16 0.1 0.12 0.23 0.21 0.11 0.1 0.15 0.17 0.16 0.2 0.13 0.13 0.23 0.18 0.15 0.14 0.12 0.14 0.16 0.15 0.17 0.11 0.22 0.13 0.15 0.14 0.17 0.13 0.1 0.15 0.09 0.09 0.11 0.16 0.1 0.08 0.1 0.1 0.13 0.09 0.14 0.08 0.12 0.13 0.14 0.08 0.11 0.11 0.13 0.15 0.1 0.1 0.11 0.08 0.08 0.09 0.17 0.12 0.1 0.09 0.1 0.09 0.08 0.07 0.13 0.11 0.11 0.06 0.16 0.1 0.1 0.07 0.12 0.09 0.08 0.11 0.15 0.13 0.06 0.1 0.11 0.09 0.08 0.07 0.12 0.1 0.12 0.12 0.12 0.09 0.1 0.1 0.08 0.1 0.09 0.09 0.09 0.1 0.07 0.08 0.14 0.08 0.1 0.07 0.12 0.1 0.07 0.08 0.1 0.08 0.06 0.07 0.05 0.07 0.09 0.1 0.06 0.07 0.08 Ala 0.21 0.19 0.24 0.35 0.33 0.17 0.16 0.26 0.22 0.22 0.2 0.22 0.21 0.27 0.31 0.34 0.24 0.18 0.21 0.22 0.24 0.2 0.16 0.31 0.22 0.32 0.32 0.38 0.19 0.25 0.15 0.24 0.28 0.19 0.24 0.19 0.33 0.23 0.17 0.23 0.24 0.31 0.3 0.26 0.22 0.2 0.16 0.18 0.28 0.23 0.22 0.21 0.2 0.26 0.2 0.19 0.18 0.15 0.22 0.16 0.17 0.19 0.18 0.24 0.22 0.13 0.34 0.18 0.14 0.17 0.19 0.18 0.22 0.26 0.22 0.2 0.2 0.2 0.33 0.28 0.16 0.23 0.17 0.24 0.27 0.24 0.23 0.21 0.16 0.24 0.17 0.17 0.16 0.23 0.2 0.15 0.17 0.14 0.18 0.26 0.13 0.17 0.19 0.14 0.22 0.26 0.2 0.19 0.28 0.2 0.19 0.26 0.29 0.18 0.24 0.18 0.2 0.33 0.17 0.2 0.23 0.23 0.31 0.2 0.27 0.32 0.26 0.14 0.3 0.16 0.26 0.3 0.16 0.26 0.27 0.26 0.19 0.19 0.28 0.26 0.25 0.21 0.2 0.17 0.2 0.41 0.24 0.15 0.2 0.18 0.22 0.23 0.3 0.31 0.15 0.23 0.29 0.21 0.25 0.18 0.25 0.22 0.32 0.24 0.23 0.32 0.28 0.16 0.2 0.22 0.35 0.25 0.28 0.29 0.26 0.18 0.17 0.21 0.24 0.27 0.15 0.24 0.28 0.21 0.22 0.19 0.2 0.18 0.24 0.3 0.18 0.16 0.26 Gln 0.49 0.39 0.47 0.54 0.38 0.45 0.43 0.47 0.45 0.49 0.47 0.38 0.44 0.45 0.39 0.4 0.47 0.43 0.36 0.47 0.49 0.45 0.48 0.5 0.44 0.53 0.44 0.42 0.34 0.34 0.4 0.55 0.48 0.53 0.51 0.38 0.36 0.46 0.44 0.38 0.29 0.35 0.34 0.36 0.46 0.51 0.37 0.42 0.38 0.46 0.52 0.46 0.38 0.44 0.43 0.38 0.42 0.42 0.45 0.4 0.43 0.4 0.35 0.49 0.4 0.32 0.4 0.39 0.43 0.43 0.26 0.43 0.44 0.49 0.49 0.47 0.45 0.48 0.46 0.42 0.39 0.37 0.48 0.55 0.49 0.53 0.41 0.37 0.38 0.54 0.43 0.38 0.35 0.4 0.39 0.4 0.42 0.54 0.42 0.55 0.38 0.49 0.41 0.39 0.44 0.46 0.44 0.4 0.5 0.43 0.48 0.45 0.48 0.5 0.47 0.39 0.48 0.45 0.5 0.38 0.45 0.53 0.55 0.38 0.54 0.46 0.35 0.41 0.45 0.48 0.64 0.45 0.52 0.44 0.39 0.56 0.42 0.45 0.41 0.4 0.42 0.43 0.41 0.52 0.48 0.53 0.44 0.53 0.35 0.5 0.47 0.4 0.48 0.41 0.4 0.48 0.5 0.44 0.53 0.5 0.48 0.49 0.49 0.49 0.48 0.52 0.42 0.43 0.44 0.4 0.46 0.5 0.57 0.54 0.47 0.45 0.43 0.43 0.58 0.45 0.39 0.36 0.38 0.29 0.48 0.37 0.35 0.28 0.35 0.44 0.37 0.39 0.38 His 0.06 0.07 0.06 0.06 0.06 0.06 0.06 0.05 0.06 0.1 0.07 0.06 0.07 0.07 0.07 0.07 0.08 0.06 0.05 0.07 0.06 0.07 0.06 0.08 0.07 0.08 0.08 0.08 0.07 0.08 0.07 0.07 0.07 0.09 0.08 0.07 0.03 0.06 0.06 0.04 0.04 0.05 0.06 0.05 0.06 0.06 0.05 0.04 0.05 0.05 0.07 0.07 0.04 0.06 0.06 0.06 0.05 0.05 0.07 0.05 0.08 0.05 0.05 0.08 0.06 0.06 0.07 0.07 0.07 0.06 0.05 0.05 0.07 0.07 0.06 0.09 0.05 0.05 0.07 0.06 0.05 0.05 0.06 0.06 0.05 0.06 0.05 0.06 0.04 0.06 0.04 0.04 0.03 0.05 0.06 0.05 0.04 0.05 0.04 0.06 0.04 0.07 0.08 0.05 0.07 0.07 0.07 0.05 0.07 0.07 0.08 0.06 0.09 0.07 0.07 0.05 0.06 0.07 0.07 0.05 0.04 0.06 0.08 0.05 0.07 0.07 0.06 0.04 0.07 0.05 0.06 0.06 0.07 0.07 0.05 0.06 0.05 0.04 0.06 0.05 0.05 0.06 0.05 0.07 0.06 0.06 0.07 0.09 0.06 0.06 0.07 0.07 0.06 0.08 0.08 0.06 0.06 0.07 0.08 0.08 0.08 0.06 0.07 0.06 0.07 0.07 0.06 0.07 0.05 0.06 0.07 0.08 0.09 0.07 0.07 0.07 0.07 0.07 0.07 0.06 0.06 0.07 0.05 0.05 0.07 0.05 0.06 0.04 0.06 0.08 0.06 0.06 0.06 Ile 0.03 0.02 0.04 0.05 0.04 0.04 0.04 0.07 0.07 0.04 0.04 0.03 0.03 0.04 0.04 0.05 0.05 0.02 0.04 0.03 0.03 0.04 0.04 0.07 0.03 0.05 0.06 0.06 0.03 0.04 0.04 0.03 0.04 0.06 0.04 0.03 0.09 0.04 0.06 0.05 0.04 0.04 0.05 0.04 0.05 0.03 0.03 0.04 0.05 0.06 0.04 0.03 0.02 0.03 0.05 0.06 0.03 0.03 0.04 0.05 0.02 0.03 0.03 0.03 0.03 0.02 0.03 0.04 0.04 0.03 0.02 0.03 0.03 0.03 0.03 0.04 0.03 0.05 0.05 0.05 0.02 0.04 0.05 0.03 0.04 0.05 0.03 0.02 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.03 0.06 0.04 0.03 0.05 0.04 0.06 0.03 0.02 0.03 0.04 0.02 0.03 0.05 0.03 0.05 0.04 0.04 0.04 0.04 0.03 0.03 0.04 0.04 0.03 0.04 0.03 0.04 0.02 0.05 0.06 0.05 0.02 0.04 0.04 0.04 0.04 0.05 0.04 0.11 0.07 0.04 0.04 0.04 0.03 0.04 0.04 0.05 0.04 0.03 0.05 0.04 0.06 0.04 0.03 0.03 0.04 0.06 0.04 0.02 0.04 0.06 0.05 0.04 0.04 0.03 0.02 0.03 0.03 0.04 0.05 0.03 0.03 0.02 0.03 0.05 0.05 0.04 0.07 0.03 0.03 0.04 0.05 0.03 0.04 0.03 0.03 0.02 0.09 0.05 0.03 0.03 0.03 0.03 0.03 0.02 0.05 0.02 Leu 0.04 0.04 0.05 0.06 0.06 0.05 0.05 0.06 0.08 0.06 0.05 0.05 0.04 0.05 0.06 0.06 0.06 0.03 0.05 0.05 0.06 0.04 0.05 0.07 0.05 0.06 0.07 0.06 0.05 0.05 0.06 0.05 0.06 0.07 0.05 0.04 0.07 0.04 0.06 0.05 0.05 0.04 0.06 0.04 0.06 0.04 0.04 0.05 0.05 0.07 0.05 0.04 0.03 0.05 0.06 0.06 0.04 0.05 0.05 0.06 0.04 0.04 0.04 0.05 0.04 0.04 0.04 0.05 0.05 0.04 0.03 0.04 0.05 0.03 0.04 0.06 0.05 0.05 0.06 0.05 0.04 0.05 0.06 0.05 0.05 0.05 0.04 0.04 0.05 0.04 0.05 0.05 0.06 0.04 0.05 0.04 0.07 0.04 0.04 0.05 0.04 0.07 0.04 0.03 0.05 0.04 0.03 0.04 0.05 0.04 0.06 0.05 0.05 0.04 0.05 0.04 0.04 0.04 0.05 0.05 0.03 0.04 0.05 0.04 0.05 0.07 0.05 0.04 0.06 0.05 0.05 0.05 0.06 0.05 0.06 0.05 0.05 0.04 0.06 0.04 0.05 0.04 0.07 0.05 0.04 0.05 0.04 0.07 0.04 0.05 0.05 0.06 0.06 0.06 0.05 0.06 0.07 0.06 0.05 0.05 0.04 0.04 0.05 0.05 0.05 0.06 0.05 0.04 0.04 0.04 0.06 0.04 0.05 0.07 0.04 0.05 0.06 0.06 0.05 0.05 0.05 0.04 0.04 0.04 0.05 0.05 0.05 0.05 0.04 0.05 0.04 0.06 0.04 Val 0.12 0.11 0.13 0.15 0.15 0.14 0.17 0.16 0.24 0.17 0.18 0.14 0.12 0.16 0.17 0.17 0.19 0.09 0.12 0.14 0.16 0.16 0.14 0.16 0.13 0.15 0.19 0.18 0.15 0.13 0.16 0.14 0.18 0.19 0.18 0.13 0.15 0.13 0.23 0.16 0.15 0.11 0.16 0.12 0.18 0.15 0.11 0.14 0.13 0.18 0.14 0.13 0.08 0.13 0.16 0.16 0.11 0.14 0.14 0.17 0.11 0.11 0.12 0.12 0.11 0.1 0.08 0.15 0.14 0.12 0.07 0.11 0.15 0.11 0.11 0.14 0.12 0.17 0.19 0.17 0.12 0.12 0.17 0.14 0.12 0.14 0.13 0.09 0.19 0.13 0.17 0.12 0.16 0.15 0.16 0.1 0.17 0.14 0.13 0.14 0.12 0.16 0.11 0.07 0.13 0.13 0.09 0.13 0.15 0.14 0.17 0.13 0.12 0.15 0.18 0.1 0.12 0.12 0.18 0.14 0.12 0.12 0.13 0.13 0.13 0.23 0.18 0.1 0.15 0.18 0.17 0.13 0.18 0.17 0.16 0.19 0.17 0.15 0.16 0.13 0.16 0.13 0.19 0.13 0.14 0.14 0.13 0.15 0.12 0.12 0.13 0.16 0.15 0.15 0.12 0.17 0.18 0.18 0.12 0.13 0.13 0.11 0.13 0.12 0.14 0.14 0.14 0.1 0.1 0.11 0.17 0.13 0.15 0.16 0.13 0.15 0.19 0.21 0.14 0.16 0.13 0.12 0.11 0.11 0.18 0.14 0.13 0.13 0.11 0.14 0.12 0.13 0.1 Phe 0.04 0.03 0.03 0.03 0.04 0.03 0.04 0.04 0.05 0.06 0.04 0.04 0.03 0.04 0.04 0.03 0.04 0.03 0.04 0.03 0.04 0.04 0.04 0.05 0.04 0.04 0.04 0.05 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.03 0.03 0.03 0.04 0.04 0.03 0.03 0.04 0.03 0.04 0.04 0.03 0.03 0.04 0.03 0.04 0.03 0.03 0.03 0.03 0.04 0.04 0.03 0.04 0.03 0.04 0.03 0.03 0.03 0.03 0.03 0.03 0.04 0.04 0.04 0.03 0.03 0.03 0.03 0.03 0.04 0.03 0.03 0.04 0.04 0.03 0.04 0.03 0.03 0.04 0.03 0.03 0.04 0.03 0.03 0.04 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.04 0.04 0.03 0.04 0.04 0.04 0.03 0.04 0.05 0.04 0.04 0.04 0.03 0.04 0.03 0.04 0.04 0.03 0.03 0.04 0.03 0.04 0.03 0.03 0.04 0.05 0.03 0.04 0.03 0.03 0.03 0.04 0.04 0.04 0.04 0.03 0.03 0.04 0.03 0.04 0.04 0.03 0.03 0.04 0.03 0.04 0.04 0.04 0.04 0.03 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.06 0.03 0.04 0.03 0.04 0.03 0.04 0.04 0.04 0.03 0.04 0.04 0.05 0.04 0.04 0.04 0.04 0.04 0.04 0.03 0.03 0.04 0.04 0.03 0.03 0.03 0.04 0.03 0.04 0.03 0.03 0.03 0.04 0.03 0.03 Tyr 0.06 0.05 0.05 0.07 0.04 0.06 0.06 0.06 0.06 0.04 0.05 0.05 0.05 0.06 0.06 0.06 0.07 0.05 0.06 0.05 0.06 0.05 0.05 0.08 0.05 0.08 0.06 0.08 0.06 0.06 0.06 0.05 0.07 0.08 0.06 0.06 0.05 0.06 0.09 0.06 0.05 0.04 0.05 0.05 0.06 0.05 0.05 0.03 0.06 0.06 0.07 0.05 0.04 0.05 0.05 0.04 0.04 0.05 0.05 0.05 0.03 0.04 0.04 0.05 0.04 0.04 0.05 0.05 0.05 0.04 0.04 0.04 0.05 0.05 0.05 0.06 0.04 0.05 0.06 0.06 0.05 0.05 0.05 0.05 0.06 0.06 0.04 0.05 0.04 0.05 0.08 0.05 0.05 0.05 0.05 0.05 0.04 0.04 0.05 0.04 0.04 0.06 0.05 0.04 0.05 0.06 0.05 0.04 0.06 0.05 0.06 0.06 0.06 0.06 0.05 0.04 0.06 0.06 0.05 0.05 0.06 0.05 0.07 0.05 0.07 0.06 0.08 0.04 0.09 0.06 0.05 0.07 0.05 0.06 0.06 0.08 0.11 0.06 0.07 0.05 0.06 0.06 0.05 0.05 0.05 0.04 0.05 0.06 0.05 0.06 0.04 0.05 0.07 0.05 0.05 0.06 0.06 0.05 0.05 0.05 0.06 0.05 0.05 0.05 0.05 0.06 0.06 0.03 0.05 0.05 0.07 0.06 0.06 0.08 0.06 0.06 0.05 0.05 0.05 0.07 0.05 0.04 0.05 0.05 0.07 0.09 0.07 0.05 0.05 0.05 0.05 0.05 0.06 NMR_METABOLITE_DATA_END #METABOLITES METABOLITES_START metabolite_name Glc Lac Pyr Cit Ala Gln His Ile Leu Val Phe Tyr METABOLITES_END #END